Can biological markers act as non-invasive, sensitive indicators of radiation-induced effects in the gastrointestinal mucosa?
- PMID: 18315578
- DOI: 10.1111/j.1365-2036.2008.03663.x
Can biological markers act as non-invasive, sensitive indicators of radiation-induced effects in the gastrointestinal mucosa?
Abstract
Background: Reliable, non-invasive biological markers of the severity of radiotherapy-induced damage to the gastrointestinal tract are not available. Clinicians continue to use symptom scores as surrogate indicators of toxicity.
Aim: To determine whether levels of potential biochemical markers of mucosal toxicity change during pelvic radiotherapy.
Methods: Fifty-nine patients (30:29 males:females) with mixed pelvic malignancies, receiving 45-70 Gy were recruited. At baseline and weeks 4 or 5 of radiotherapy, blood samples for citrulline, C-reactive protein, eosinophil cationic protein and stool samples for faecal calprotectin were obtained. Symptoms were measured using the Inflammatory Bowel Disease Questionnaire - Bowel Subset, Radiation Therapy Oncology Group and Vaizey Incontinence Questionnaires. Paired t-tests of change in marker values were calculated.
Results: Citrulline (P = 0.02) and faecal calprotectin (P = 0.01) values changed significantly between baseline and 4/5 weeks. Inflammatory Bowel Disease Questionnaire - Bowel Subset fell significantly (mean fall = 10 points, s.d.: 8.9). Changes in markers did not correlate with symptoms.
Conclusions: Some biochemical markers of mucosal toxicity change significantly during treatment. Further studies must investigate the timing of changes of these biochemical markers, their relationship to gastrointestinal physiological change and the radiotherapy dose delivered to the gastrointestinal tract and whether changes in markers acutely can predict the degree of long-term gastrointestinal dysfunction.
Similar articles
-
A modified inflammatory bowel disease questionnaire and the Vaizey Incontinence questionnaire are more sensitive measures of acute gastrointestinal toxicity during pelvic radiotherapy than RTOG grading.Int J Radiat Oncol Biol Phys. 2006 Apr 1;64(5):1432-41. doi: 10.1016/j.ijrobp.2005.10.007. Int J Radiat Oncol Biol Phys. 2006. PMID: 16580497
-
Elevated C-reactive protein levels are not a feature of uncomplicated radiation-induced bowel injury.Eur J Cancer Care (Engl). 2007 Jul;16(4):346-50. doi: 10.1111/j.1365-2354.2006.00759.x. Eur J Cancer Care (Engl). 2007. PMID: 17587359
-
Faecal DNA and calprotectin as biomarkers of acute intestinal toxicity in patients undergoing pelvic radiotherapy.Aliment Pharmacol Ther. 2009 Jul 1;30(2):175-85. doi: 10.1111/j.1365-2036.2009.04019.x. Epub 2009 Apr 15. Aliment Pharmacol Ther. 2009. PMID: 19392859
-
Questions and answers on the role of faecal calprotectin as a biological marker in inflammatory bowel disease.Dig Liver Dis. 2009 Jan;41(1):56-66. doi: 10.1016/j.dld.2008.05.008. Epub 2008 Jul 3. Dig Liver Dis. 2009. PMID: 18602356 Review.
-
The example of gastrointestinal damage induced by ionising radiation: are there accessible markers?Cell Mol Biol (Noisy-le-grand). 2001 May;47(3):427-35. Cell Mol Biol (Noisy-le-grand). 2001. PMID: 11441949 Review.
Cited by
-
Gut microbial dysbiosis may predict diarrhea and fatigue in patients undergoing pelvic cancer radiotherapy: a pilot study.PLoS One. 2015 May 8;10(5):e0126312. doi: 10.1371/journal.pone.0126312. eCollection 2015. PLoS One. 2015. PMID: 25955845 Free PMC article.
-
Exploring a link between fatigue and intestinal injury during pelvic radiotherapy.Oncologist. 2010;15(9):1009-15. doi: 10.1634/theoncologist.2010-0097. Epub 2010 Jul 28. Oncologist. 2010. PMID: 20667967 Free PMC article.
-
Acute intestinal failure in critically ill patients: is plasma citrulline the right marker?Intensive Care Med. 2011 Jun;37(6):911-7. doi: 10.1007/s00134-011-2172-x. Epub 2011 Mar 12. Intensive Care Med. 2011. PMID: 21400011 Review.
-
Biomarkers of chemotherapy-induced diarrhoea: a clinical study of intestinal microbiome alterations, inflammation and circulating matrix metalloproteinases.Support Care Cancer. 2013 Jul;21(7):1843-52. doi: 10.1007/s00520-013-1741-7. Epub 2013 Feb 10. Support Care Cancer. 2013. PMID: 23397098
-
Fecal calprotectin use in inflammatory bowel disease and beyond: A mini-review.Can J Gastroenterol Hepatol. 2015 Apr;29(3):157-63. doi: 10.1155/2015/950286. Can J Gastroenterol Hepatol. 2015. PMID: 25855880 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials